Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-20
DOI
10.1007/s00262-020-02637-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors
- (2018) Malaka Ameratunga et al. EUROPEAN JOURNAL OF CANCER
- Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
- (2018) Aya Nakaya et al. International Journal of Clinical Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients
- (2018) Yann-Alexandre Vano et al. PLoS One
- The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer
- (2018) Tatsunori Kiriu et al. PLoS One
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
- (2018) Aly-Khan A. Lalani et al. Journal for ImmunoTherapy of Cancer
- Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients
- (2018) Monica Khunger et al. PLoS One
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025
- (2017) Bernard Escudier et al. EUROPEAN UROLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutrophils dominate the immune cell composition in non-small cell lung cancer
- (2017) Julia Kargl et al. Nature Communications
- Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer
- (2017) Takayuki Shiroyama et al. Cancer Medicine
- Neutrophil to lymphocyte ratio associated with prognosis of lung cancer
- (2016) V. Bar-Ad et al. Clinical & Translational Oncology
- The Clinical Use of the Neutrophil to Lymphocyte Ratio (NLR) in Urothelial Cancer: A Systematic Review
- (2016) Michele Marchioni et al. Clinical Genitourinary Cancer
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of intra-tumoral tumour-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio is an independent prognostic factor in non-small cell lung cancer
- (2015) Nigar Dirican et al. Clinical Respiratory Journal
- Pseudoprogression and Immune-Related Response in Solid Tumors
- (2015) Victoria L. Chiou et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Tumor associated macrophages and neutrophils in cancer
- (2013) Maria Rosaria Galdiero et al. IMMUNOBIOLOGY
- Recent advances in the treatment of metastatic renal cell carcinoma
- (2013) Hideyuki Abe et al. INTERNATIONAL JOURNAL OF UROLOGY
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
- (2009) F. Colotta et al. CARCINOGENESIS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started